Details for Patent: 8,349,840
✉ Email this page to a colleague
Which drugs does patent 8,349,840 protect, and when does it expire?
Patent 8,349,840 protects REXULTI and is included in one NDA.
Protection for REXULTI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-six patent family members in twenty-nine countries.
Summary for Patent: 8,349,840
Title: | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Abstract: | The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. ##STR00001## |
Inventor(s): | Yamashita; Hiroshi (Tokushima, JP), Ito; Nobuaki (Tokushima, JP), Miyamura; Shin (Tokushima, JP), Oshima; Kunio (Tokushima, JP), Matsubara; Jun (Tokushima, JP), Kuroda; Hideaki (Tokushima, JP), Takahashi; Haruka (Tokushima, JP), Shimizu; Satoshi (Tokushima, JP), Tanaka; Tatsuyoshi (Tokushima, JP) |
Assignee: | Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) |
Application Number: | 12/970,690 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,349,840 |
Patent Claim Types: see list of patent claims | Composition; Compound; Use; |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 8,349,840
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-001 | Jul 10, 2015 | AB | RX | Yes | No | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-002 | Jul 10, 2015 | AB | RX | Yes | No | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-003 | Jul 10, 2015 | AB | RX | Yes | No | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-004 | Jul 10, 2015 | AB | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-005 | Jul 10, 2015 | AB | RX | Yes | No | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-006 | Jul 10, 2015 | AB | RX | Yes | No | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,349,840
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 2005-116698 | Apr 14, 2005 |
International Family Members for US Patent 8,349,840
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 1869025 | ⤷ Try for Free | 300946 | Netherlands | ⤷ Try for Free |
European Patent Office | 1869025 | ⤷ Try for Free | 122018000088 | Germany | ⤷ Try for Free |
European Patent Office | 1869025 | ⤷ Try for Free | PA2018509 | Lithuania | ⤷ Try for Free |
European Patent Office | 1869025 | ⤷ Try for Free | CA 2018 00028 | Denmark | ⤷ Try for Free |
European Patent Office | 1869025 | ⤷ Try for Free | LUC00086 | Luxembourg | ⤷ Try for Free |
European Patent Office | 1869025 | ⤷ Try for Free | 32/2018 | Austria | ⤷ Try for Free |
European Patent Office | 1869025 | ⤷ Try for Free | 2018C/037 | Belgium | ⤷ Try for Free |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |